Coarctation of Aorta
Conditions
Brief summary
This is a systemic research of Chinese aortic coarctation patients, aiming to determine risk factors and serial biomarkers of aortic coarctation in prognosis.
Detailed description
The goal is to determine how much the left ventricle remodeling pre-operation and how it changes in the following-up duration after surgery, so does in the blood pressure and heart function. Risk factors associated with complications and prognosis are investigated and analyzed. Identification of novel biomarkers is needed to help predicting the prognosis, such as the left ventricle anti-remodeling, heart function and blood pressure improvement, as well as the exercise tolerance post-operation. The findings of this study will help the investigators developping new tests to monitor affected patients and optimize the operation as well as the follow-up procedure.
Interventions
None listed
Sponsors
Beijing Anzhen Hospital
Bayi Children's Hospital Affiliated to PLA Army General Hospital, China
Capital Institute of Pediatrics, China
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of isolated coarctation of the aorta, or accompanied with atrial septal defect(ASD), ventricular septal defect (VSD), patent ductus arteriosus( PDA), patent foramen ovale (PFO); * Patients who can cooperation with study procedures.
Exclusion criteria
* Co-morbidities that may independently affect cardiovascular function, including associated complicated congenital heart disease, such as hypoplastic left heart syndrome (HLHS), interruption of aortic arch (IAA), Shone Syndrome, moderate and severe mitral stenosis; * History of known vasculopathy, genetic syndromes, diabetes mellitus, hyperlipoidemia or other cardiovascular risk factors.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in left ventricular mass | Prior to primary treatment and during follow-up visit(one month to 20 years for retrospective cohort and one year for prospective cohort) | Left ventricular mass will be measured by 2D echocardiography. For the retrospective cohort, the data is collected from the cases' medical record, and during follow-up visit. |
| Hypertension | one month to 20 years after primary treatment for retrospective cohort and one year after primary treatment for prospective cohort | Both resting blood pressure and exercise-related blood pressure will be assessed for patients above 5 years old during the follow-up visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Left ventricular systolic heart function of longitudinal myocardium | one month to 20 years after primary treatment for retrospective cohort and one year after primary treatment for prospective cohort | Left ventricular systolic heart function of longitudinal myocardium assessed by echocardiography (M mode Doppler). |
| Exercise tolerance | one month to 20 years after primary treatment for retrospective cohort and one year after primary treatment for prospective cohort | Six minutes walking distance will be recorded and analyzed to evaluate the exercise tolerance. Echocardiographic images will be obtained after six minutes walking to assess the reserve function of left ventricle. Blood pressure will also be taken immediately after the Six minutes walking to analyze exercise-induced hypertension. |
| Biomarkers of vascular inflammation | Prior to primary treatment and during follow-up visit(one month to 20 years for retrospective cohort and one year for prospective cohort) | Biomarkers of inflammation (hs-CRP). For the retrospective cohort, the data is collected from the cases' medical record, and during follow-up visit. |
| Biomarkers of left ventricle remodeling | For the retrospective cohort, follow-up visit of 1 month to 20 years after primary treatment. For the prospective cohort, the data is collected prior to primary treatment and during follow-up visit of one year after primary treatment | Biomarkers of left ventricle remodeling (ST2) |
| Left ventricular systolic function | one month to 20 years after primary treatment for retrospective cohort and one year after primary treatment for prospective cohort | Left ventricular systolic function assessed by echocardiography |
| Biomarkers of hypertension phenotype related to aortic coarctation | one month to 20 years after primary treatment for retrospective cohort and one year after primary treatment for prospective cohort | Biomarkers of hypertension phenotype related to aortic coarctation |
| Recoarctation | one month to 20 years after primary treatment for retrospective cohort and one year after primary treatment for prospective cohort | Recoarctation assessed by echocardiography or computed tomography angiography. |
| All-cause death | 20 years after primary treatment for retrospective cohort and one year after primary treatment for prospective cohort | The data is collected during follow-up visit at follow-up time point. |
| Biomarkers of left heart function | Prior to primary treatment and during follow-up visit(one month to 20 years for retrospective cohort and one year for prospective cohort) | Biomarkers of left heart function (BNP). For the retrospective cohort, the data is collected from the cases' medical record, and during follow-up visit. |
| Left ventricular diastolic function | one month to 20 years after primary treatment for retrospective cohort and one year after primary treatment for prospective cohort | Left ventricular diastolic function assessed by echocardiography (TDI) |
Countries
China
Contacts
Primary ContactYuan WANG, PhD
Backup ContactYan GU, PhD
Outcome results
None listed